Binding and uptake of novel RGD micelles to the αvβ 3 integrin receptor for targeted drug delivery

Journal of Drug Targeting

Volumn 22, Issue 6, 2014, Pages 518-527

  Raj, April ^a   Saraf, Poonam ^a   Javali, Narashima Murthy ^a   Li, Xiaoling ^a   Jasti, Bhaskara ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Confocal microscopy; Cytotoxicity; Fluorescence polarization; Micelle stability; Receptor mediated endocytosis; RGD peptide amphiphile

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; PACLITAXEL; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; MICELLE; OLIGOPEPTIDE; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE OVEREXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IN VITRO STUDY; INTERNALIZATION; MELANOMA CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; TRANSITION TEMPERATURE; METABOLISM; MICELLE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DELIVERY SYSTEMS; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; INTEGRIN ALPHAVBETA3; MICELLES; MICROSCOPY, CONFOCAL; OLIGOPEPTIDES; PACLITAXEL; PROTEIN BINDING;

EID: 84902246959     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.897709     Document Type: Article

References (39)

1. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010;6: 714-29.
2. Adiseshaiah PP, Hall JB, Mcneil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010;2: 99-112.
3. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2: 751-60.
4. Wang W, Wu Q, Pasuelo M, et al. Probing for integrin avb3 binding of RGD peptides using fluorescence polarization. Bioconjug Chem 2005;16: 729-34.
5. Singh R, Lillard Jr JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86: 215-23.
6. Xiong X-B, Mahmud A, Uludag H, Lavasanifar A. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)- b-poly(E-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. Biomacromolecules 2007;8: 874-84. (Pubitemid 46488467)
7. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48: 101-11.
8. Kabanov AV, Lemieux P, Vinogradov S, Alakhov V. Pluronic block copolymers: novel functional molecules for gene therapy. Adv Drug Deliv Rev 2002;54: 223-33.
9. Gaucher G, Dufresne MH, Sant VP, et al. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005;109: 169-88.
10. Niece KL, Hartgerink JD, Donners JJ, Stupp SI. Self-assembly combining two bioactive peptide-amphiphile molecules into nanofibers by electrostatic attraction. J Am Chem Soc 2003;125: 7146-7. (Pubitemid 36798942)
11. Rangel-Yagul CO, Pessoa Jr A, Blankschtein D. Two-phase aqueous micellar systems - an alternative method for protein purification. Braz J Chem Eng 2004;21: 531-44.
12. Shen SI, Kotamraj PR, Bhattacharya S, et al. Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agents. J Drug Target 2007; 15: 51-8.
13. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2011;73: 137-72.
14. Chen JX, Wang HY, Li C, et al. Construction of surfactant-like tetra-tail amphiphilic peptide with RGD ligand for encapsulation of porphyrin for photodynamic therapy. Biomaterials 2011;32: 1678-84.
15. Aulisa L, Forraz N, Mcguckin C, Hartgerink JD. Inhibition of cancer cell proliferation by designed peptide amphiphiles. Acta Biomater 2009;5: 842-53.
16. Javali NM, Raj A, Saraf P, et al. Fatty acid-RGD peptide amphiphile micelles as potential paclitaxel delivery carriers to alpha(v)beta (3)integrin overexpressing tumors. Pharm Res 2012; 29: 3347-61.
17. Wang YG, Wang X, Zhang YF, et al. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrinoverexpressing tumor vasculature and tumor cells. J Drug Target 2009;17: 459-67.
18. Rerat V, Dive G, Cordi AA, et al. avb3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem 2009;52: 7029-43.
19. Ratnikov BI, Rozanov DV, Postnova TI, et al. An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem 2002;277: 7377-85.
20. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 2006;3: 472-87.
21. Cheng C, Komljenovic D, Pan L, et al. Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG. Hell J Nucl Med 2011;14: 15-20.
22. Aznavoorian S, Stracke ML, Parsons J, et al. Integrin alphavbeta3 mediates chemotactic and haptotactic motility in human melanoma cells through different signaling pathways. J Biol Chem 1996;271: 3247-54.
23. Sturm RA, Satyamoorthy K, Meier F, et al. Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res 2002;62: 226-32.
24. Li E, Brown SL, Stupack DG, et al. Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol 2001;75: 5405-9.
25. Pfaff A, Schallon A, Ruhland TM, et al. Magnetic and fluorescent glycopolymer hybrid nanoparticles for intranuclear optical imaging. Biomacromolecules 2011;12: 3805-11.
26. Adams ML, Kwon GS. The effects of acyl chain length on the micelle properties of poly(ethylene oxide)-block-poly(N-hexyl-Laspartamide)- acyl conjugates. J Biomater Sci Polym Ed 2002;13: 991-1006. (Pubitemid 35345399)
27. Wiradharma N, Tong YW, Yang YY. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 2009;30: 3100-9.
28. Dong H, Dube N, Shu JY, et al. Long-circulating 15 nm micelles based on amphiphilic 3-helix peptide-PEG conjugates. ACS Nano 2012;6: 5320-9.
29. Welsh DJ, Smith DK. Comparing dendritic and self-assembly strategies to multivalency-RGD peptide-integrin interactions. Org Biomol Chem 2011;9: 4795-801.
30. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010;145: 182-95.
31. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-blockpoly (L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002;54: 169-90.
32. Mahmud A, Lavasanifar A. The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells. Colloids Surf B Biointerfaces 2005;45: 82-9.
33. Garanger E, Boturyn D, Jin Z, et al. New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. Mol Ther 2005;12: 1168-75.
34. Jin ZH, Furukawa T, Galibert M, et al. Noninvasive visualization and quantification of tumor alphaVbeta3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFTc(- RGDfK-)4. Nucl Med Biol 2011;38: 529-40.
35. Bodary SC, Mclean JW. The integrin beta 1 subunit associates with the vitronectin receptor alpha v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line. J Biol Chem 1990; 265: 5938-41.
36. Raymond E, Hanauske A, Faivre S, et al. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anticancer Drugs 1997;8: 379-85.
37. Cai LL, Liu P, Li X, et al. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomed 2011;6: 3499-508.
38. Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009;133: 11-17.
39. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 2005;13: 73-80.